What are the definitions, causes, and management differences between type I (hypoxemic) respiratory failure and type II (hypercapnic) respiratory failure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 9, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Type 1 vs Type 2 Respiratory Failure: Definitions and Clinical Distinctions

Type 1 respiratory failure is hypoxemic failure (PaO₂ <8 kPa or <60 mmHg) with normal or low PaCO₂, while Type 2 respiratory failure is hypercapnic failure (PaO₂ <8 kPa AND PaCO₂ >6 kPa or >45 mmHg), often with respiratory acidosis (pH <7.35). 1

Core Pathophysiologic Differences

Type 1 (Hypoxemic) Respiratory Failure

  • Primary problem: Failure of oxygenation
  • Blood gas pattern: Low PaO₂ with normal or low PaCO₂
  • Mechanism: Results from V/Q mismatch, intrapulmonary shunt, diffusion limitation, or low inspired oxygen 2, 3
  • Common causes: Pneumonia, ARDS, pulmonary embolism, pneumothorax, acute asthma, interstitial lung disease 4

Type 2 (Hypercapnic) Respiratory Failure

  • Primary problem: Failure of ventilation (alveolar hypoventilation)
  • Blood gas pattern: Low PaO₂ AND elevated PaCO₂ (>6 kPa/>45 mmHg)
  • Mechanism: Reduced alveolar ventilation from pump failure, increased dead space, or excessive CO₂ production 2, 5
  • Common causes: COPD exacerbations, neuromuscular disease, chest wall deformity, obesity hypoventilation, respiratory muscle fatigue 4, 1

Critical Management Distinctions

Oxygen Therapy Targets

Type 1 (Hypoxemic):

  • Target SpO₂: 94-98% 4
  • Can use high-flow oxygen or reservoir masks at 15 L/min if SpO₂ <85% 4
  • Oxygen is the primary therapeutic intervention

Type 2 (Hypercapnic):

  • Target SpO₂: 88-92% 4, 6
  • Critical caveat: Excessive oxygen worsens hypercapnia and respiratory acidosis 4, 7
  • Use controlled oxygen delivery (24-28% Venturi mask or 1-2 L/min nasal cannulae) 4
  • Never give oxygen alone without checking for hypercapnia - this can cause life-threatening CO₂ retention 7

Ventilatory Support Strategy

Type 1 (Hypoxemic):

  • High-flow nasal cannula (HFNC) preferred over conventional oxygen therapy 8
  • CPAP may be beneficial, particularly in cardiogenic pulmonary edema 4
  • NIV has limited role in de novo hypoxemic failure (higher failure rates) 9
  • Lower threshold for intubation if worsening despite oxygen 8

Type 2 (Hypercapnic):

  • NIV is first-line treatment when pH <7.35 and PaCO₂ >6.5 kPa despite optimal medical therapy 1, 6
  • Start NIV if respiratory acidosis persists >30 minutes after standard medical management 4
  • Bi-level pressure support ventilators are recommended 1
  • NIV reduces mortality, intubation rates, and ICU admissions in COPD 1, 6

Recognition and Monitoring

When to Suspect Type 2 Failure

  • High-risk populations: COPD, neuromuscular disease, chest wall deformity, obesity, morbid obesity 4, 1
  • Clinical clues: Patients may not appear dyspneic despite severe respiratory failure (especially neuromuscular disease) 7
  • Evidence of chronic hypercapnia: High bicarbonate (>28 mmol/L) with elevated PaCO₂ but pH ≥7.35 4

Blood Gas Monitoring Requirements

  • Type 2 failure: Recheck blood gases at 30-60 minutes after initiating oxygen therapy to detect rising PaCO₂ or falling pH 4
  • Even if initial PaCO₂ is normal in at-risk patients, repeat blood gases to ensure no CO₂ retention develops 4
  • Transcutaneous CO₂ monitoring can facilitate ongoing assessment 6

Common Pitfalls to Avoid

  1. Giving high-flow oxygen to undiagnosed breathless patients: Always check blood gases first in patients with COPD or risk factors for hypercapnia 4, 7

  2. Sudden oxygen cessation in Type 2 failure: Can cause life-threatening rebound hypoxemia - step down gradually to 88-92% target 4

  3. Using oxygen alone in hypercapnic patients: Hypoxemia with saturations <95% in patients with diaphragmatic weakness requires ventilatory support (NIV), not just oxygen 7

  4. Delayed NIV initiation: When pH <7.35 and PaCO₂ >6 kPa persist despite medical therapy, start NIV promptly 4, 6

  5. Missing chronic hypercapnia: High bicarbonate levels indicate chronic CO₂ retention - these patients need 88-92% target range even if acutely stable 4

Prognostic Indicators

Type 2 failure with NIV: Improvement in pH and respiratory rate within 1-2 hours predicts success; worsening indicates need for intubation 6

Type 1 failure: Higher mortality risk, particularly when associated with ARDS or severe hypoxemia despite high oxygen requirements 8, 9

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.